ABBVON

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Name ABBVON

Rank No.3316

Market Cap $0.00

Fully Diluted Market Cap $0.00

Market Share %

Trading Vol/Market Cap (24H) 872,142.74%

Circulation Supply 123.08541488

Max Supply 0

Total Supply 123.08541488

Circulation Rate %

Issue Date --

The price at which the asset was first issued --

All-Time High 237.64005999136555, 2026-03-05

Lowest Price 193.3720963640878, 2026-04-29

Public Blockchain ABBVON

Introduction AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Sector

Social Media

• Twitter

• Official Website
• Block Explorer

Fund Flow Analysis

etfindex:mc_etfindex_source Disclaimer: Data provided by cmc and should not be considered as investment advice.